DMT.

ClinicalTrials.gov v2 verification on 2026-04-24 | Overall status: NOT_YET_RECRUITING | Exact phase: PHASE1 | Lead sponsor: GH Research Ireland Limited | Conditions: Healthy Adult | Interventions: DRUG: 5 Methoxy N,N Dimethyltryptamine; DEVICE: GH001 Aerosol Delivery System | Registry start date type: ESTIMATED (2026-04).

ClinicalTrials.gov v2 sync on 2026-04-18 | Overall status: RECRUITING | Exact phase: NA | Lead sponsor: University Hospital, Basel, Switzerland | Conditions: Major Depressive Disorder; Psychedelic Experiences | Interventions: N,N-Dimethyltryptamine; Placebo; Propofol; no sedation

ClinicalTrials.gov v2 verification on 2026-04-24 | Overall status: RECRUITING | Exact phase: PHASE1 | Lead sponsor: University Hospital, Basel, Switzerland | Conditions: 5-methoxy-dimethyltryptamine (5-MeO-DMT) | Interventions: DRUG: 0.2 mg/min 5-MeO-DMT; DRUG: 0.4 mg/min 5-MeO-DMT; DRUG: 0.6 mg/min 5-MeO-DMT; DRUG: 0.8 mg/min 5-MeO-DMT; DRUG: Placebo | Registry start date type: ESTIMATED (2026-03-31).

Last checked 2026-05-16 UTC. Claim boundary: registry and company-source backfill only; active-not-recruiting Phase 2 status and company topline claims do not establish approval, label, reimbursement, access, independent efficacy confirmation, broad safety, or Phase 3 success. Registry: randomized quadruple-masked active-controlled Phase 2a in GAD; estimated n=36; two CYB004 medicine sessions ~3 weeks apart plus EMBARK psychotherapy; primary outcome HAM-A across Day 364; actual primary completion 2025-10-14.

ClinicalTrials.gov manual QA on 2026-04-17 | Exact registry status: Withdrawn | Official title: Trifecta Research Study: Examining Hormone Replacement Therapy, Magnetic e-Resonance Therapy, Ibogaine, and 5-MeO-DMT in the Treatment of Posttraumatic Stress Disorder and Traumatic Brain Injury-related Cognitive Symptoms | Sponsor: Johns Hopkins University | Conditions: PTSD - Post Traumatic Stress Disorder; Cognitive Dysfunction; Brain Trauma; Brain Injuries | Interventions: Hormone Replacement Therapy (HRT); Magnetic Resonance Therapy (MeRT); ibogaine with magnesium treatment; 5-MeO-DMT | Study type: Interventional

ClinicalTrials.gov v2 verification on 2026-04-24 | Overall status: COMPLETED | Exact phase: PHASE2 | Lead sponsor: Beckley Psytech Limited | Conditions: Treatment Resistant Depression | Interventions: DRUG: BPL-003; DRUG: BPL-003 | Asset identity checked against atai/Beckley 2025-10-16 source: BPL-003 is intranasal mebufotenin (5-MeO-DMT) benzoate.

ClinicalTrials.gov v2 sync on 2026-04-10 | Overall status: COMPLETED | Exact phase: Phase 2 | Lead sponsor: GH Research Ireland Limited | Conditions: Treatment-resistant Depression

ClinicalTrials.gov manual QA on 2026-04-17 | Status: Completed | Sponsor: University Hospital, Basel, Switzerland | Official title: Acute Dose-dependent Effects of DMT-bolus Applications in Healthy Subjects: A Placebo-controlled Cross-over Study (DMT BDR-Study) | Condition: Healthy | Intervention: N,N-Dimethyltryptamine bolus dose arms plus placebo | Study type: Interventional | Official title: Acute Dose-dependent Effects of DMT-bolus Applications in Healthy Subjects: A Placebo-controlled Cross-over Study (DMT BDR-Study).

ClinicalTrials.gov manual QA on 2026-04-17 | Status: Completed | Sponsor: Biomind Labs Inc. | Official title: A Phase 1/2 Randomized, Double-Blind, Placebo-Controlled Trial of Multiple Sublingual 5-MeO-DMT Microdoses for Reducing Anxiety and/or Depression in Patients With Mild Cognitive Impairment. | Condition: Mild Cognitive Impairment; Anxiety State; Depression Anxiety Disorder | Intervention: Sublingual 5-MeO-DMT microdoses plus psychiatric, cognitive, biochemical, and EEG assessments | Study type: Interventional

ClinicalTrials.gov v2 sync on 2026-04-18 | Overall status: COMPLETED | Exact phase: Phase 1 | Lead sponsor: Insel Gruppe AG, University Hospital Bern | Conditions: Neuropharmacological Investigation of Ayahuasca Constituents DMT and Harmine | Interventions: N,N-dimethyltryptamine (DMT) + harmine; Placebo

ClinicalTrials.gov manual QA on 2026-04-17 | Status: Completed | Sponsor: Biomind Labs Inc. | Official title: A Phase 1/2 Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate Safety, Tolerability and Efficacy of Multiple Sublingual Microdoses of 5-MeO-DMT in Reducing Symptoms of Depression and/or Anxiety. | Condition: Healthy Volunteers | Intervention: BMND08 sublingual 5-MeO-DMT formulation plus monitoring procedures | Study type: Interventional

ClinicalTrials.gov v2 sync on 2026-04-10 | Overall status: TERMINATED | Exact phase: Phase 2 | Lead sponsor: GH Research Ireland Limited | Conditions: Bipolar II Disorder

ClinicalTrials.gov v2 sync on 2026-04-10 | Overall status: TERMINATED | Exact phase: Phase 2 | Lead sponsor: GH Research Ireland Limited | Conditions: Postpartum Depression; Postnatal Depression

ClinicalTrials.gov v2 sync on 2026-04-18 | Overall status: ACTIVE_NOT_RECRUITING | Exact phase: PHASE1 | Lead sponsor: Algernon Pharmaceuticals | Conditions: Stroke | Interventions: N,N-Dimethyltryptamine; Placebo | Notes: Tracker status mapped to Active because ACTIVE_NOT_RECRUITING is not an available status option.

ClinicalTrials.gov v2 sync on 2026-04-10 | Overall status: RECRUITING | Exact phase: Phase 1 | Lead sponsor: GH Research Ireland Limited | Conditions: Healthy Volunteers

ClinicalTrials.gov v2 sync on 2026-04-18 | Overall status: COMPLETED | Exact phase: PHASE2 | Lead sponsor: Universidade Federal do Rio Grande do Norte | Conditions: Depressive Disorder; Depression, Unipolar | Interventions: N,N-Dimethyltryptamine

ClinicalTrials.gov manual QA on 2026-04-17 | Status: Completed | Sponsor: University Hospital, Basel, Switzerland | Official title: Acute Dose-dependent Effects of DMT in Healthy Subjects: A Placebo-controlled Cross-over Study | Condition: Healthy | Intervention: N,N-Dimethyltryptamine dose-ranging arms plus placebo | Study type: Interventional

ClinicalTrials.gov manual QA on 2026-04-17 | Status: Completed | Sponsor: Usona Institute | Official title: A Phase 1, First-in-human, Double-blind, Placebo-controlled, Randomized, Single- and Multiple-ascending-dose Study to Determine the Safety, Tolerability, and Pharmacokinetics of 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) Administered by Intramuscular Injection in Healthy Subjects | Condition: Pharmacokinetics; Safety; Tolerability | Intervention: 5-methoxy-N,N-dimethyltryptamine succinate salt; Placebo | Study type: Interventional

ClinicalTrials.gov v2 sync on 2026-04-18 | Overall status: COMPLETED | Exact phase: PHASE1 | Lead sponsor: Reconnect Labs | Conditions: Healthy | Interventions: Dimethyltryptamin (DMT) & Harmine | Notes: DMT + harmine combination tagged as Ayahuasca, DMT because the registry explicitly lists both ayahuasca-relevant constituents.

ClinicalTrials.gov v2 sync on 2026-04-18 | Overall status: COMPLETED | Exact phase: PHASE1 | Lead sponsor: Universidade Federal do Rio Grande do Norte | Conditions: Safety Issues; Healthy Volunteers | Interventions: N,N-Dimethyltryptamine; Placebo

ClinicalTrials.gov v2 sync on 2026-04-18 | Overall status: COMPLETED | Exact phase: Early Phase 1 | Lead sponsor: Milan Scheidegger | Conditions: Healthy Participants | Interventions: DMT + harmine; Placebo | Notes: Summary explicitly frames Ayahuasca as the relevant plant preparation context.

ClinicalTrials.gov v2 sync on 2026-04-10 | Overall status: COMPLETED | Exact phase: Phase 1 | Lead sponsor: GH Research Ireland Limited | Conditions: Healthy Volunteers

ClinicalTrials.gov v2 sync on 2026-04-10 | Overall status: COMPLETED | Exact phase: Phase 1, Phase 2 | Lead sponsor: GH Research Ireland Limited | Conditions: Treatment Resistant Depression; Major Depressive Disorder; Depression

ClinicalTrials.gov manual QA on 2026-04-17 | Status: Completed | Sponsor: Beckley Psytech Limited | Official title: A Double-Blind, Randomized, Phase 1, First-in-Human, Single Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetic Profile of Intranasal 5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT) in Healthy Subjects | Condition: Pharmacokinetics in Healthy Adults | Intervention: 5-MeO-DMT; Placebo | Study type: Interventional

ClinicalTrials.gov manual QA on 2026-04-17 | Status: Completed | Sponsor: University Hospital, Basel, Switzerland | Official title: Effects of Dimethyltryptamine (DMT) in Healthy Subjects: A Placebo-controlled Cross-over Study | Condition: Healthy | Intervention: Dimethyltryptamine (DMT); Saline | Study type: Interventional

ClinicalTrials.gov v2 sync on 2026-04-18 | Overall status: COMPLETED | Exact phase: EARLY_PHASE1 | Lead sponsor: Psychiatric University Hospital, Zurich | Conditions: Emotions; Mood; Cognitive Function 1, Social; Empathy | Interventions: DMT; Harmine; Placebo (Harmine); Placebo (DMT) | Notes: DMT + harmine combination tagged as Ayahuasca, DMT because the registry explicitly lists both ayahuasca-relevant constituents.

ClinicalTrials.gov v2 sync on 2026-04-10 | Overall status: COMPLETED | Exact phase: Phase 1 | Lead sponsor: GH Research Ireland Limited | Conditions: Healthy Volunteers